These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28993264)

  • 1. Sensory-mechanical effects of a dual bronchodilator and its anticholinergic component in COPD.
    O'Donnell DE; Elbehairy AF; Faisal A; Neder JA; Webb KA;
    Respir Physiol Neurobiol; 2018 Jan; 247():116-125. PubMed ID: 28993264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
    Donohue JF; Singh D; Munzu C; Kilbride S; Church A
    Respir Med; 2016 Mar; 112():65-74. PubMed ID: 26797016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute bronchodilator therapy does not reduce wasted ventilation during exercise in COPD.
    Elbehairy AF; Webb KA; Laveneziana P; Domnik NJ; Neder JA; O'Donnell DE;
    Respir Physiol Neurobiol; 2018 Jun; 252-253():64-71. PubMed ID: 29578103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
    Rodrigo GJ; Neffen H
    Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD.
    O'Donnell DE; Hamilton AL; Webb KA
    J Appl Physiol (1985); 2006 Oct; 101(4):1025-35. PubMed ID: 16675610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD.
    Man WD; Mustfa N; Nikoletou D; Kaul S; Hart N; Rafferty GF; Donaldson N; Polkey MI; Moxham J
    Thorax; 2004 Jun; 59(6):471-6. PubMed ID: 15170026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inspiratory muscle training reduces diaphragm activation and dyspnea during exercise in COPD.
    Langer D; Ciavaglia C; Faisal A; Webb KA; Neder JA; Gosselink R; Dacha S; Topalovic M; Ivanova A; O'Donnell DE
    J Appl Physiol (1985); 2018 Aug; 125(2):381-392. PubMed ID: 29543134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.
    Maltais F; Kirsten AM; Hamilton A; De Sousa D; Voß F; Decramer M
    Respir Res; 2016 Jul; 17(1):77. PubMed ID: 27383762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of fluticasone/salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD.
    Guenette JA; Webb KA; O'Donnell DE
    Respir Med; 2013 May; 107(5):708-16. PubMed ID: 23421968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea.
    Diba C; King GG; Berend N; Salome CM
    Respir Med; 2011 Sep; 105(9):1345-51. PubMed ID: 21482091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L; Kerwin E; Collison K; Nelsen L; Wu W; Yang S; Pascoe S
    Respir Med; 2017 Oct; 131():148-157. PubMed ID: 28947022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of exertional dyspnoea in symptomatic smokers without COPD.
    Elbehairy AF; Guenette JA; Faisal A; Ciavaglia CE; Webb KA; Jensen D; Ramsook AH; Neder JA; O'Donnell DE;
    Eur Respir J; 2016 Sep; 48(3):694-705. PubMed ID: 27492828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
    Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
    Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deterioration of Nighttime Respiratory Mechanics in COPD: Impact of Bronchodilator Therapy.
    Domnik NJ; James MD; Scheeren RE; Ayoo GA; Taylor SM; Di Luch AT; Milne KM; Vincent SG; Phillips DB; Elbehairy AF; Crinion SJ; Driver HS; Neder JA; O'Donnell DE
    Chest; 2021 Jan; 159(1):116-127. PubMed ID: 32603714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD.
    O'Donnell DE; Laveneziana P; Ora J; Webb KA; Lam YM; Ofir D
    Thorax; 2009 Mar; 64(3):216-23. PubMed ID: 19052054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study assessing the effect of bronchodilator on dynamic hyperinflation in LAM.
    Baldi BG; de Albuquerque AL; Pimenta SP; Salge JM; Kairalla RA; Carvalho CR
    Respir Med; 2013 Nov; 107(11):1773-80. PubMed ID: 24064347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.